Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis ; day:23 ; month:7 ; year:2024 ; pages:1-12
Osteoporosis international ; (23.7.2024), 1-12
- Urheber
-
Reginster, Jean-Yves
Czerwinski, Edward
Wilk, Krzysztof
Borowy, Przemysław
Strzelecka, Anna
Budlewski, Tomasz
Janowska-Maus, Monika
Szymanowski, Krzysztof
Kwiatek, Joanna
Postol, Svitlana
Põder, Airi
Supronik, Jerzy
Kim, SungHyun
Suh, JeeHye
Han, NooRi
Kim, NaHyun
Bae, SeoHee
Silverman, Stuart L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00198-024-07161-x
- URN
-
urn:nbn:de:101:1-2410090808386.663967623685
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reginster, Jean-Yves
- Czerwinski, Edward
- Wilk, Krzysztof
- Borowy, Przemysław
- Strzelecka, Anna
- Budlewski, Tomasz
- Janowska-Maus, Monika
- Szymanowski, Krzysztof
- Kwiatek, Joanna
- Postol, Svitlana
- Põder, Airi
- Supronik, Jerzy
- Kim, SungHyun
- Suh, JeeHye
- Han, NooRi
- Kim, NaHyun
- Bae, SeoHee
- Silverman, Stuart L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia
Quality of life in post-menopausal osteoporosis
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia
Quality of life in post-menopausal osteoporosis
Randomized Double-Blind Comparative Study of First Global Denosumab Biosimilar in Oncology
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Postmenopausal osteoporosis
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study
Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia